A Phase I, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers
Latest Information Update: 12 Apr 2024
At a glance
- Drugs ATL 001 (Primary)
- Indications Erythropoietic protoporphyria
- Focus Adverse reactions
- Sponsors Atlas Molecular Pharma
Most Recent Events
- 09 Apr 2024 Status changed from active, no longer recruiting to completed.
- 02 Apr 2024 Planned End Date changed from 20 Apr 2024 to 8 Apr 2024.
- 02 Apr 2024 Planned primary completion date changed from 20 Apr 2024 to 8 Apr 2024.